Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Vascular Cell Function and Arterial Remodeling.
Reads0
Chats0
TLDR
The role of SGLT2 inhibitors in mediating the vascular actions of these drugs remains to be established as important off-target effects have been identified as discussed by the authors, and future studies distinguishing drug- versus class-specific effects may optimize the selection of specific SGLTs in patients with distinct cardiovascular pathologies.Abstract:
Cardiovascular disease is the leading cause of morbidity and mortality in diabetes. Recent clinical studies indicate that sodium-glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in patients with diabetes. The mechanism underlying the beneficial effect of SGLT2 inhibitors is not completely clear but may involve direct actions on vascular cells. SGLT2 inhibitors increase the bioavailability of endothelium-derived nitric oxide and thereby restore endothelium-dependent vasodilation in diabetes. In addition, SGLT2 inhibitors favorably regulate the proliferation, migration, differentiation, survival, and senescence of endothelial cells (ECs). Moreover, they exert potent antioxidant and anti-inflammatory effects in ECs. SGLT2 inhibitors also inhibit the contraction of vascular smooth muscle cells and block the proliferation and migration of these cells. Furthermore, studies demonstrate that SGLT2 inhibitors prevent postangioplasty restenosis, maladaptive remodeling of the vasculature in pulmonary arterial hypertension, the formation of abdominal aortic aneurysms, and the acceleration of arterial stiffness in diabetes. However, the role of SGLT2 in mediating the vascular actions of these drugs remains to be established as important off-target effects of SGLT2 inhibitors have been identified. Future studies distinguishing drug- versus class-specific effects may optimize the selection of specific SGLT2 inhibitors in patients with distinct cardiovascular pathologies.read more
Citations
More filters
Journal ArticleDOI
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Teresa Salvatore,Raffaele Galiero,Alfredo Caturano,Luca Rinaldi,Anna Di Martino,Gaetana Albanese,Jessica Di Salvo,R. Epifani,Raffaele Marfella,Giovanni Docimo,Miriam Lettieri,Celestino Sardu,Ferdinando Carlo Sasso +12 more
TL;DR: Correcting cardiorenal risk factors, metabolic adjustments ameliorating myocardial substrate utilization, and optimization of ventricular loading conditions through effects on diuresis, natriureis, and vascular function appear to be the main underlying mechanisms for the observed cardi Lorenal protection.
Journal ArticleDOI
Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes.
Panagiotis Theofilis,Marios Sagris,Evangelos Oikonomou,Alexios S. Antonopoulos,Gerasimos Siasos,Costas Tsioufis,Dimitris Tousoulis +6 more
TL;DR: In this paper , the authors provided the milestones and the latest mechanistic evidence of SGLT2 inhibition in heart failure, including the restoration of autophagy which may be significant in the reversal of the aforementioned heart failure pathophysiology according to a latest hypotheses.
Journal ArticleDOI
Amelioration of endothelial dysfunction by sodium glucose co‐transporter 2 inhibitors: pieces of the puzzle explaining their cardiovascular protection
Xiaoling Li,Benedikt Preckel,Jeroen Hermanides,Markus W. Hollmann,Coert J. Zuurbier,Nina C. Weber +5 more
TL;DR: This review focuses on the most recent progress and existing gaps in preclinical investigations concerning the direct effects of SGLT‐2is on endothelial dysfunction and the mechanisms underlying such effects.
Journal ArticleDOI
Impact of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging—What Do We Know So Far? (A Narrative Review)
TL;DR: Clinical studies have demonstrated the active role of vascular endothelium in the onset of cardiovascular diseases and sodium–glucose cotransporter 2 inhibitors decrease arterial stiffness and vascular resistance.
Journal ArticleDOI
SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
Roko Skrabic,Marko Kumric,Josip Vrdoljak,Doris Rusic,Ivna Skrabic,Marino Vilovic,Dinko Martinovic,Vid Duplancic,Tina Ticinovic Kurir,Josko Bozic +9 more
TL;DR: Although SGLT2i provide clinicians with an exciting new treatment option for patients with chronic kidney disease, further research is needed to determine which subgroups of patients with CKD will benefit the most, and which the least, from this therapeutical option.
References
More filters
Journal ArticleDOI
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
Diabetes Control,David M. Nathan,Saul M. Genuth,John M. Lachin,Patricia A. Cleary,O Crofford,Matthew M. Davis,Larry Rand,Carolyn Siebert +8 more
TL;DR: Intensive therapy effectively delays the onset and slows the progression of diabetic retinopathy, nephropathy, and neuropathy in patients with IDDM.
Journal ArticleDOI
Report of the expert committee on the diagnosis and classification of diabetes mellitus
James R. Gavin,K. G M M Alberti,Mayer B. Davidson,Ralph A. DeFronzo,Allan Drash,Steven G. Gabbe,Saul M. Genuth,Maureen I. Harris,Richard Kahn,Harry Keen,William C. Knowler,Harold E. Lebovitz,Noel K. Maclaren,Jerry P. Palmer,Philip Raskin,Robert A. Rizza,Michael P. Stern +16 more
TL;DR: It was deemed essential to develop an appropriate, uniform terminology and a functional, working classification of diabetes that reflects the current knowledge about the disease.
Journal ArticleDOI
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman,Christoph Wanner,John M. Lachin,David Fitchett,Erich Bluhmki,Stefan Hantel,Michaela Mattheus,Theresa Devins,Odd Erik Johansen,Hans-Juergen Woerle,Uli C. Broedl,Silvio E. Inzucchi +11 more
TL;DR: Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care.
Journal ArticleDOI
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
TL;DR: Despite an early loss of glycemic differences, a continued reduction in microvascular risk and emergent risk reductions for myocardial infarction and death from any cause were observed during 10 years of post-trial follow-up.
Journal ArticleDOI
Canagliflozin and cardiovascular and renal events in type 2 diabetes
Bruce Neal,Vlado Perkovic,Vlado Perkovic,Kenneth W. Mahaffey,Dick de Zeeuw,Greg Fulcher,Ngozi Erondu,Wayne Shaw,Gordon Law,Mehul Desai,David R. Matthews +10 more
TL;DR: Patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal.
Related Papers (5)
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review
Gary D. Lopaschuk,Subodh Verma +1 more